JYNNEOS Vaccine Fails to Stop Monkeypox Disease in the United States; Disappointing Results on Protection From Male Sexually Transmitted Rash; McCullough's substack is prescient

I share because as a scientist, I could not write this any better, McCullough as the tacit lead (with Risch & at times Oskoui & Ladapo) of the COVID anti-lockdown anti-fraud mRNA technology movement

‘President Biden dropped the Monkeypox National Emergency Declaration on January 31, 2023, after it was clear that human to human transmission occurred in largely younger men having sex with other men. Older individuals after age 50 appeared to be protected from childhood smallpox vaccination and those without dangerous sexual behavioral profiles were not at risk. Additionally, Monkeypox (MPOX)

was readily treatable with tecovirimat, a safe and effective medication available orally and intravenously.

Approximately 1.2 million Americans were encouraged to take the Bavarian Nordic Jynneos vaccine without any prior randomized trials demonstrating safety or efficacy in humans. Now the medical community is learning about the failure of the Jynneos vaccine in the peer reviewed literature. Because case-control methodology tends to overestimate vaccine efficacy and is not an adequate replacement for a randomized trial, when we see vaccine efficacy far less than 90%, the real protection is likely to be very disappointing.

Deputy et al, used the EPIC electronic medical record August 15, 2022, and November 19, 2022 to evaluate the impact of the MPOX vaccine and found among 2193 case patients and 8319 control (HIV) patients, 25 case patients and 335 control patients received two doses (full vaccination), among whom the estimated adjusted vaccine effectiveness was 66.0% (95% confidence interval [CI], 47.4 to 78.1), and 146 case patients and 1000 control patients received one dose (partial vaccination), among whom the estimated adjusted vaccine effectiveness was 35.8% (95% CI, 22.1 to 47.1).

Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, Dalton AF, Sweet C, Cohn AC, Little DR, Cohen AL, Sandmann D, Payne DC, Gerhart JL, Feldstein LR. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med. 2023 May 18. doi: 10.1056/NEJMoa2215201. Epub ahead of print. PMID: 37199451.

A more appropriate control group being unvaccinated gay men without HIV may have demonstrated even worse VE for the vaccine. Thus we can conclude that the Jynneos vaccine as modest to little efficacy in stopping MPOX.

The CDC reported an outbreak from April 17 to May 5, 2023, a total of 12 confirmed and one probable case of MPOX were reported to the Chicago Department of Public Health. All cases were among symptomatic men. None of the patients have been hospitalized. Nine (69%) of 13 cases were among men who had received 2 JYNNEOS vaccine doses. So two thirds of cases being fully vaccinated suggests the vaccine is a bust.

Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, Dalton AF, Sweet C, Cohn AC, Little DR, Cohen AL, Sandmann D, Payne DC, Gerhart JL, Feldstein LR. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med. 2023 May 18. doi: 10.1056/NEJMoa2215201. Epub ahead of print. PMID: 37199451.

CDC Monkeypox Alert: Distributed via the CDC Health Alert Network May 15, 2023, 9:00 AM ET’

JYNNEOS Vaccine Fails to Stop Monkeypox Disease in the United States